Condition: Granulomatosis With Polyangiitis · Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis · Sponsor: Assistance Publique - Hôpitaux de Paris
The purpose of this study is to identify the most promising therapeutic strategy for patients with granulomatosis with polyangiitis and inadequate response to standard of care therapy. It will evaluate the efficacy to induce remission of three different salvage strategies including: a combination of rituximab with addition of a conventional disease-modifying antirheumatic drugs (either methotrexate, azathioprine or mycophenolate mofetil, but preferentially methotrexate); tocilizumab; or tofacitinib.
This description comes directly from the study's public registry record.
Jonathan London, MD · +33 1 44 64 16 02 · jlondon@hopital-dcss.org
Alice CAMARA · 01 58 41 12 11 · alice.camara@aphp.fr
Always discuss trial participation with your own doctor first.
| Hôpital de la Croix Saint Simon | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04871191